Cargando…

Update on Anti-EGFR Therapy

Detalles Bibliográficos
Autores principales:	Chua, Daniel, Fasching, Peter, Ma, Brigette, Thongprasert, Sumitra, Wirth, Lori
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740841/ https://www.ncbi.nlm.nih.gov/pubmed/19750187 http://dx.doi.org/10.1155/2009/157964

Ejemplares similares

ESMO Women for Oncology 2016: a very personal tale of my professional life in Asia
por: Thongprasert, Sumitra
Publicado: (2017)

Unexpected insights for anti-EGFR cancer therapy
por: Depeille, Philippe, et al.
Publicado: (2015)

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
por: Shi, Yuankai, et al.
Publicado: (2014)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

Prevalence and relationship between major depressive disorder and lung cancer: a cross-sectional study
por: Maneeton, Benchalak, et al.
Publicado: (2014)

Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
por: Park, Dong-Guk
Publicado: (2011)

Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer
por: Loong, Herbert H., et al.
Publicado: (2009)

Adjuvant EGFR-TKIs-based therapy: are we ready?
por: Tam, Terence
Publicado: (2020)

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
por: Mohan, Sumitra, et al.
Publicado: (2014)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Hepatorenal syndrome: Update on diagnosis and therapy
por: Acevedo, Juan G, et al.
Publicado: (2017)

Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated
por: Kanda, Naoko
Publicado: (2021)

Global Implementation of Precision Oncology
por: Yam, Clinton, et al.
Publicado: (2021)

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
por: Eniu, Alexandru, et al.
Publicado: (2019)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
por: Rosati, Gerardo, et al.
Publicado: (2022)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
por: Safyan, Rachael A., et al.
Publicado: (2018)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Update on mesenchymal stem cell therapies for cartilage disorders
por: Paschos, Nikolaos K, et al.
Publicado: (2017)

p53: updates on mechanisms, biology and therapy (II)
por: Lane, David P, et al.
Publicado: (2019)

p53: updates on mechanisms, biology and therapy (I)
por: Lane, David P, et al.
Publicado: (2019)

Prosthetic Joint Infection: Updates on Prevention, Diagnosis and Therapy
por: Gallo, Jiri
Publicado: (2020)

News and Updates from 2022 on Antioxidant and Anti-Inflammatory Properties of Marine Products
por: Vasarri, Marzia, et al.
Publicado: (2022)

The subcostal nerve as the target for nerve stimulator–guided transversus abdominis plane blocks - Commentary
por: Bakshi, Sumitra G
Publicado: (2019)

The Digital Era and the Future of Pediatric Surgery
por: Biswas, Sumitra Kumar
Publicado: (2021)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

Pain and Inflammation: Update on Emerging Phytotherapy, Zootherapy, and Nutritional Therapies
por: Owoyele, Bamidele V., et al.
Publicado: (2016)

Commentary on “Gene Therapy Approach for Intervertebral Disc Degeneration: An Update”
por: Kang, James D.
Publicado: (2020)

Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Updates and New Perspectives on Adenoviral Gene Therapy and Vaccine Vectors
por: Dobner, Thomas, et al.
Publicado: (2023)

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
Publicado: (2022)

Unarranged territory in uncommon EGFR mutations
por: Fujii, Hiroyuki, et al.
Publicado: (2022)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Cystacin C-based eGFR and Creatinine Clearance-based eGFR in Patients with Severe Motor and Intellectual Disabilities
por: Tamura, Kouichi, et al.
Publicado: (2023)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vg3bbd89antm5mg63s2jo65avt